The hnRNP family: insights into their role in health and disease by unknown
1 3
Hum Genet (2016) 135:851–867
DOI 10.1007/s00439-016-1683-5
REVIEW
The hnRNP family: insights into their role in health and disease
Thomas Geuens1,2 · Delphine Bouhy1,2 · Vincent Timmerman1,2 
Received: 23 March 2016 / Accepted: 9 May 2016 / Published online: 23 May 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
MBP  Myelin basic protein
NF  Neurofilament
NLS  Nuclear localization signal
PTBP1  Polypyrimidine tract-binding protein 1
qRRM  Quasi RNA recognition motif
RBD  RNA-binding domain
RBP  RNA-binding protein
RGG box  Arg-Gly-Gly box
RNP  Ribonucleoprotein
RRM  RNA recognition motif
SMA  Spinal muscular atrophy
SMN  Survival motor neuron
snRNP  Small nuclear ribonucleoprotein
TGF-β  Transforming growth factor-beta
UTR  Untranslated region
15-LOX  15-Lipoxygenase
Introduction
Many ribonucleoproteins (RNPs) assemble on to newly 
created transcripts in the nucleus of a eukaryotic cell. 
Among these RNPs are the heterogeneous nuclear ribo-
nucleoproteins (hnRNPs). They assist in controlling the 
maturation of newly formed heterogeneous nuclear RNAs 
(hnRNAs/pre-mRNAs) into messenger RNAs (mRNAs), 
stabilize mRNA during their cellular transport and con-
trol their translation. Considering their functional diversity 
and complexity, hnRNPs act as key proteins in the cellular 
nucleic acid metabolism (Fig. 1) (Dreyfuss et al. 1993).
The role of hnRNPs in regulating gene expression has 
gained an increasing interest in disease research. The 
expression level of hnRNPs is altered in many types of 
cancer, suggesting their role in tumorigenesis. In addi-
tion to cancer, many hnRNPs were also linked to various 
Abstract Heterogeneous nuclear ribonucleoproteins 
(hnRNPs) represent a large family of RNA-binding pro-
teins (RBPs) that contribute to multiple aspects of nucleic 
acid metabolism including alternative splicing, mRNA sta-
bilization, and transcriptional and translational regulation. 
Many hnRNPs share general features, but differ in domain 
composition and functional properties. This review will 
discuss the current knowledge about the different hnRNP 
family members, focusing on their structural and functional 
divergence. Additionally, we will highlight their involve-
ment in neurodegenerative diseases and cancer, and the 
potential to develop RNA-based therapies.
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neurodegenerative diseases, such as spinal muscular atro-
phy (SMA), amyotrophic lateral sclerosis (ALS), Alz-
heimer’s disease (AD) and fronto-temporal lobe demen-
tia (FTLD). As neurons are non-dividing cells, therefore 
needing a tight regulation of mRNA homeostasis, they are 
highly vulnerable to dysfunction of RNA-binding proteins 
(RBPs), including the hnRNPs.
Because of the growing repertoire of different types of 
RBPs, it is still unclear how and when they are triggered 
to interact and functionally complement each other. The 
hnRNPs were initially categorized according to their RNA-
binding domains (RBDs) composition (Dreyfuss et al. 1993), 
but this classification is not exclusive and many different 
hnRNPs share common features. This review will focus on 
the “standard” hnRNPs (Han et al. 2010) (Fig. 2), discuss the 
overall features of the hnRNP family and highlight their mul-
tifunctionality in cellular homeostasis in health and disease.
The hnRNP family
The 40S core particle was the first mRNA–protein complex, 
isolated by sucrose density gradients, which comprised 
hnRNPs A/B and C (Beyer et al. 1977). Later on, several 
other hnRNPs were identified as RBP complexes via pull-
down and UV-cross-linking experiments (van Eekelen et al. 
1981). These complexes were shown to be created out of 
20 major types of hnRNPs (Table 1) and minor hnRNPs, 
where the latter ones have been found to be less expressed 
and do not have hnRNA-binding capacities, but may regu-
late major hnRNPs (Dreyfuss et al. 1993).
The functions of hnRNPs vary according to their cellular 
localization. The mechanisms that regulate the nucleo-cyto-
plasmic shuttling are, therefore, of extreme importance. 
Most of the hnRNP proteins possess a conventional nuclear 
localization signal (NLS) and are predominantly present in 
the nucleus during steady state. They are able to translo-
cate in the cytosol upon post-translational stimulation or by 
the recruitment of other hnRNPs (Fig. 1) (Han et al. 2010). 
The hnRNP proteins frequently undergo post-translational 
modifications, leading to changes in biological activity and 
subcellular localization. Reported post-translational modi-
fications on hnRNPs include methylation, phosphorylation, 
ubiquitination and sumoylation (Chaudhury et al. 2010a).
Structure
Four unique RBDs were identified in hnRNP proteins: the 
RNA recognition motif (RRM), the quasi-RRM, a glycine-
rich domain constituting an RGG box and a KH domain 
(Fig. 2).
The most common RBD is the RNA recognition motif 
(RRM). Eukaryotic RRMs are structurally characterized 
by four β-sheets and two α-helices (βαββαβ) together with 
two conserved RNP1 octameric and RNP2 hexameric 
sequences that are positioned approximately 30 residues 
apart from each other (Dreyfuss et al. 1988). It is known 
that the variable loops, connecting the β-sheets, contribute 
to its RNA-binding specificity (Görlach et al. 1992).
The RGG box is characterized by contiguous clusters 
containing aromatic Phe and Tyr residues intercalated 
between tripeptide repeats of Arg-Gly-Gly amino acids 
(Kiledjian and Dreyfuss 1992). The glycine-rich domain is 
often seen as an auxiliary domain, responsible for homol-
ogous and heterologous interactions with other hnRNPs 
(Cartegni et al. 1996).
The KH domain is originally found in hnRNP K (KH; 
K-Homology) as triple repeats (Siomi et al. 1993). All KH 
domains present in hnRNPs are characterized by three-
stranded antiparallel β-sheet packed against three α-helices 
(βααββα). A flexible loop that links two α-helices in the 
KH core specifically interacts with RNA (Fig. 3) (Jensen 
et al. 2000). The KH domains are split into two divisions 
based on their N- or C-terminal extensions. Type I KH 
domains have a βα extension in their C-terminus, whereas 
Type II KH domains have an αβ extension in their N-termi-
nus (Grishin 2001).
Next to RBDs, hnRNPs frequently contain auxiliary 
domains, such as proline-, glycine- or acid-rich domains 
(Dreyfuss et al. 2002). Not all RBDs are exclusive and the 
specificity in RNA binding is largely mediated by the 3D 
structure of the protein where the structural regions around 
the RBDs fine-tune the RNA–protein interaction.
The modularity created by the combination of these dif-
ferent domains including RNA-binding domains (RBDs) 
and auxiliary domains (Fig. 2) increases the functional 
diversity of hnRNPs (Table 1).
Fig. 1  The diverse nuclear and cytoplasmic functions of hnRNPs. 
The hnRNPs have been found to be involved in different stages of the 
mRNA metabolism. They constantly undergo a binding and release 
from their target mRNAs depending on the modification needed. The 
hnRNPs bind, together with several transcription factors and other 
RBPs, to promotor and enhancer sequences to direct transcription (1). 
As soon as a part of the newly formed transcript is released by the 
RNA polymerase II, the hnRNPs and snRNPs bind rapidly to their 
nascent transcript to stabilize it (2). Once the correct RBP complexes 
are formed, intronic sequences are removed by the spliceosome. 
Many hnRNPs are known to regulate alternative splicing leading to 
exon skipping or intron retention (3). Mature mRNAs are stabilized 
by the binding of several types of RBPs, including hnRNPs, which 
are found necessary for export through the nuclear pore complex 
(NPC) and its transport through the cytoplasm until translation initi-
ates (4). As hnRNPs have the capacity to bind to the 3′- and 5′-UTRs 
of mRNAs, they can control translational repression or enhancement. 
Depending on the composition of complexes at the sites where trans-
lation initiation factors assemble, the choice to start translation or not 
will be made (5). Please note that not all different hnRNP subgroup 
members are involved in every nuclear or cytoplasmic function. 
The different hnRNPs are color coded, but do not represent specific 
hnRNP members
▸
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Functional diversity of hnRNPs
hnRNP A/B
The hnRNPs A/B are divided into four subgroups: hnRNP 
A1, A2/B1, A3 and A0 for which very little is known. 
Most studies were performed on hnRNP A1 and A2/B1, 
which are highly expressed cellular proteins (Dreyfuss 
et al. 2002) and are found to be involved in mRNA transla-
tion (Park et al. 2015) and splicing (Mayeda and Krainer 
1992). In addition, hnRNP A2/B1 plays an important role 
in oligodendrocytic and neuronal mRNA trafficking (Shan 
et al. 2003). The hnRNP A2/B1 is important for the correct 
localization of transcripts containing an A2 response ele-
ment (A2RE) (Shan et al. 2000) or A2RE-like sequences, 
such as the myelin basic protein (MBP) (Makeyev and 
Liebhaber 2002) or Ca2+/calmodulin-dependent protein 
kinase II (CaMKII), activity-regulated cytoskeleton-associ-
ated protein (Arc) and neurogranin (NRGN) mRNA (Gao 
et al. 2008). The interactions of hnRNP A2/B1 with A2RE 
are induced upon elevated cellular Ca2+ levels and mediate 
the dendritic transport of mRNAs (Muslimov et al. 2014). 
The hnRNP A3 recognize single-stranded telomeric DNA, 
but due to limited functional studies its cellular function 
remains largely unknown (Huang et al. 2010).
Recent research identified an additional role of hnRNP 
A2/B1 in the loading of exosomes. These are plasma 
membrane-derived extracellular vesicles mediating cell–
cell communication and carrying selected proteins, lipids 
and RNA (Théry et al. 2002). The exact mechanism that 
regulates the sorting of exosomal RNA remains poorly 
understood. Recently, hnRNP A2/B1 was shown to bind 
miRNA and directs it to the exosomes for incorporation 
(Villarroya-Beltri et al. 2013). This interaction is driven by 
the recognition of a GGAG motif in the 3′-end of miRNAs 
and is dependent on the sumoylation of hnRNP A2/B1 (Vil-
larroya-Beltri et al. 2013, 2014). These findings were fur-
ther supported by the presence of hnRNP A2/B1-miRNA 
complexes in the exosomes found in human cerebrospinal 
fluid (Tietje et al. 2014). Similarly, hnRNPA1 and C are 
able to bind exosomal miRNA; however, no binding motif 
has been identified so far (Villarroya-Beltri et al. 2013). 
Exosomes are gaining more attention in therapeutic strate-
gies, as they can be potentially used as vehicles for gene 
therapy and to deliver vaccines (Lai and Breakefield 2012).
hnRNP C
The hnRNP C is believed to be the founder of the hnRNP 
family and was one of the first hnRNPs found to be 
Fig. 2  The hnRNP family. The hnRNPs have different molecular 
weights ranging from 34 to 120 kDa and are named alphabetically 
from hnRNP A1 to hnRNP U. Many hnRNPs are found to be present 
in the same complexes, all suggesting that multiple hnRNPs share a 
common structure and function. As shown in the overview, several 
structural domains are shared between different family members. 
The members of the hnRNP family are built up of four unique RNA-
binding domains (RBDs). It is obvious that multiple family members 
carry the same RBDs, partly explaining their shared RNA-binding 
properties: RRM RNA recognition motif, qRRM quasi-RNA recogni-
tion motif and KH K-homology domain, RGG RNA-binding domain 
consisting of Arg-Gly-Gly repeats. The sizes of these 16 common 
hnRNPs are drawn relative to each other
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involved in RNA splicing (Han et al. 2010). Two human 
spliceoforms have been identified as hnRNP C1 and 
hnRNP C2, differing from each other by 13 amino acids. 
The hnRNP C contains only one RNA-binding domain, 
consisting of an acid-rich auxiliary domain located in the 
N- or C-terminal RRM (Swanson et al. 1987). Because 
hnRNP C has only one RBD it has to oligomerize with 
other hnRNP C monomers to be able to form a strong and 
specific RNA interaction. This oligomerization capacity is 
mediated by a leucine zipper motif that lies in the auxiliary 
domain of hnRNP C (Cieniková et al. 2015). This syner-
gistic interplay between hnRNP C monomers is necessary 
to form hnRNP C tetramers to measure the length of newly 
formed transcripts. They bind selectively to unstructured 
RNA stretches that have a length of more than 200–300 
nucleotides, enabling hnRNP C to sort transcripts accord-
ing to their size (McCloskey et al. 2012). Besides pack-
aging newly formed transcripts, hnRNP C also stimulates 
the translation of the c-myc transcription factor (Han et al. 
2010).
hnRNP D (AUF1)
The hnRNP D family, also known as AUF1, comprises four 
different proteins generated by alternative splicing. These 
four isoforms constitute two non-identical RRM domains. 
The hnRNP D forms stable dimers to increase their bind-
ing specificity to mRNA targets (Fialcowitz et al. 2005). 
The four isoforms have a high affinity toward AU-rich and 
mRNA-destabilizing sequences located in the 3′-UTR of 
mRNAs (Fialcowitz et al. 2005). Therefore, rapid mRNA 
decay is most often mediated by the association of hnRNP 
D (Fialcowitz et al. 2005). Although hnRNP D is mostly 
known for mRNA decay, it also stimulates the transcrip-
tion of the telomerase reverse transcriptase (TERT) gene, 
which is required for telomere maintenance (Pont et al. 
2012). In addition, this RBP interacts directly with telom-
eric repeat sequences and further highlights its telomeric 
function (Enokizono et al. 2005).
hnRNP E
The hnRNPs E1 and E2, together with hnRNP K, are the 
only ones containing KH domains to bind RNA (Fig. 3). 
The hnRNP E1 and E2 are often referred to as poly(C)
binding proteins, PCBP1 and PCBP2, respectively, and 
classified together with hnRNP E3 (PCBP3) and hnRNP 
E4 (PCBP4) (Leffers et al. 1995) which are exclusively 
cytoplasmic and therefore not catalogued as hnRNPs (Chk-
heidze and Liebhaber 2003).
hnRNP E1 and E2 bind to the 3′-UTR of all three neuro-
filament isoforms (NFL, NFM and NFH), which belong to the 
family of intermediate filaments and are highly expressed in 
neurons (Thyagarajan and Szaro 2004). The strength of inter-
action between NF transcripts and hnRNP E1 and E2 changes 
during postnatal development in the rat cerebral cortex (Thya-
garajan and Szaro 2008). Besides its crucial role in mRNA 
stabilization, the hnRNP E1 is also known as a modulator of 
Fig. 3  KH–RNA interaction. The KH domain was identified in mul-
tiple RNA-binding proteins and characterized by a 45 amino acid 
repeat that can be split into two groups. The Type I KH domains 
have a βα extension in their C-terminus, whereas the Type II KH 
domains have an αβ extension in their N-terminus. The core region 
of the KH domain is characterized by three-stranded antiparallel 
β-sheets together with three α-helices (βααββα). It is believed that 
the nucleotide recognition of the KH domain is determined by a con-
served GxxG loop (highlighted in red) in the nucleotide stretch that 
links two α-helices in the KH core (a). This leads to the orientation 
of four nucleotides toward the groove in the protein structure where 
the nucleotide (backbone colored in light and dark blue) recogni-
tion is mainly determined by hydrophobic interactions and hydrogen 
bonds. Besides sequence-specific recognition, the overall shape of the 
KH hydrophobic groove, which is determined by the conformation of 
multiple side chains, is equally important in KH–RNA recognition 
(b). It was shown by using surface plasmon resonance that the KH 
domain shows a high affinity for poly(C) repeats, more specifically, 
the affinity was higher for C-tetrads than for C-triplets. Protein mod-
eling was performed based on the crystal structure of a KH domain 
bound to a TCCCT DNA sequence, pdb file, 3VKE, and by using the 
Yasara software (http://www.yasara.org)
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alternative splicing, e.g., of CD44. When hnRNP E1 is phos-
phorylated by Pak1, it displays an increased nuclear retention, 
leading to alternative splicing and exon inclusion of a CD44 
mini-gene (Meng et al. 2007). Furthermore, hnRNP E1 is 
found to negatively control the alternative splicing of CD44 
by forming a complex with THAP11, an important protein for 
pluripotency and cell growth (Lian et al. 2012). The hnRNP 
E1 overexpression induces the down-regulation of several vari-
ants of the CD44 transcript (Zhang et al. 2010). Less informa-
tion is known for the role of hnRNP E1 in the processing of 
viral RNA, where it interacts with the exon splice site in exon 
3 of HIV1 and thereby alters its protein synthesis (Hadian 
et al. 2009). Besides their roles in mRNA stability and alter-
native splicing, hnRNP E1, together with E2, exerts crucial 
roles in transcriptional and translational regulation. Although 
hnRNP E1 is classified as an RBP, it also has the capacity to 
bind to ssDNA. The hnRNP E1 binds, in combination with 
hnRNP E2 and hnRNP K, to a 26 nucleotide polypyrimidine 
stretch in the proximal promotor of the µ-opoid receptor gene, 
thereby stimulating its transcription in neuronal cells (Malik 
et al. 2006), while hnRNP E3 works as a repressor (Choi et al. 
2008). Interestingly, hnRNP E1 and E2 depleted cells revealed 
a marked alteration in the polyadenylation of transcripts. These 
alterations were seen on transcripts bearing a C-rich motif 
30–40 bases, 5′ to their polyadenylation sites (Ji et al. 2013). 
The best-known and most studied function of hnRNP E1 is its 
role in translational control. This RBP stimulates translation by 
interacting with a stem loop in the IRES of its target mRNAs, 
as seen for poliovirus (Gamarnik and Andino 1997) and 
Bag1 mRNA (Pickering et al. 2003). In contrast, it has been 
proven that hnRNP E1 causes translational repression of the 
human papillomavirus type 16 (HPV-16) (Collier et al. 1998), 
15-lipoxygenase (15-LOX) (Ostareck et al. 1997), interleukin-
like EMT inducer (ILEI) and disabled-2 (Dab2) (Chaudhury 
et al. 2010b) mRNAs. Taking together, hnRNP E1 together 
with hnRNP E2 mediate crucial steps of the RNA metabolism, 
like the regulation in transcription and translation, mRNA sta-
bility and splicing. In contrast to the functional pleiotropy of 
its close family members, hnRNP E3 is less studied and only 
reported as a transcriptional repressor.
hnRNP F/H
Unlike most hnRNPs, hnRNP F and H appear to bind only 
three consecutive guanines (G-tracts), which are capable 
of creating G-quadruplexes. The RRMs present in hnRNP 
F and H are not conserved and are therefore alternatively 
described as quasi-RRMs (qRRMs) (Dominguez et al. 
2010; Samatanga et al. 2013). These qRRMs interact with 
RNA in a specific way by ‘encaging’ the G-tract RNA 
sequence (Dominguez et al. 2010). This affinity for repeat 
sequences allows hnRNP F to recognize the (UUAGG) 
RNA repeat present in telomeric RNA, suggesting a role 
for hnRNP F in telomere maintenance (López de Silanes 
et al. 2010). The best-known functions of hnRNP F and 
H, in combination with other hnRNPs, is the regulation of 
alternative splicing (Gautrey et al. 2015).
hnRNP G (RBMX)
The hnRNP G, alternatively named as RBMX referring 
to the gene’s position on the X chromosome, is the only 
hnRNP that can be glycosylated, which is found to be 
necessary for protein–protein interactions (Soulard et al. 
1993). The RBMY is located on the Y chromosome and is 
thought to have originated from hnRNP G by retrotrans-
positional events (Elliott et al. 2000) and is only expressed 
in the testis (Liu et al. 2009). The hnRNP G contains a 
glycine-rich auxiliary domain that is located in the N- and 
C-terminal RRM (Han et al. 2010). It is found as a splicing 
factor, activating the inclusion of exon 7 of the SMN gene 
(Moursy et al. 2014) and inhibiting the splicing of exon 10 
of the tau gene (Wang et al. 2011). Thus, so far, hnRNP G 
is only found to be involved in modulating mRNA splicing.
hnRNP I (PTBP1)/L
The hnRNP I is also known as polypyrimidine tract-bind-
ing protein 1 (PTBP1) because it regulates splicing by 
interacting with polypyrimidine stretches often located at 
the branch point upstream of exons (Patton et al. 1991). 
This RNA-binding capacity is mediated by four RRMs 
found with high sequence similarity in hnRNP L and bind-
ing preferentially to CA repeats or CA-rich elements (Han 
et al. 2010). Surface plasmon resonance spectroscopy 
underscored the importance of all four RRMs in the con-
tribution to RNA binding and adopting the typical βαββαβ 
topology (Zhang et al. 2013b). The hnRNP I and L are 
involved in multiple cellular processes, including mRNA 
stabilization (Söderberg et al. 2007) and translation (Bush-
ell et al. 2006), but are most probably better known for 
their activities in pre-mRNA processing.
The hnRNP L is a regulator of inducible exon skipping 
in CD45 mRNA upon T cell activation (Melton et al. 2007). 
Exon binding leads to the repression of strong splice sites 
and to the enhancement of weak splice sites, possibly by the 
stabilization of snRNP binding (Motta-Mena et al. 2010). 
Similarly, the hnRNP I expression level controls alternate 
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5′ and 3′ splice site usage of its target mRNAs (Hamid and 
Makeyev 2014) as well as the alternative splicing of the 
BCL-X gene, important in cell survival and apoptosis. Both 
hnRNP I and L interact with each other to suppress exon P3A 
splicing of the CHRNA1 gene, encoding one of the subunits 
of the nicotinic acetylcholine receptor (Rahman et al. 2013). 
Furthermore, both hnRNPs regulate Cat-1 mRNA translation 
upon starvation conditions (Majumder et al. 2009).
Besides their prominent roles in alternative splicing, 
the two hnRNPs were recently found to be associated with 
miRNA-mediated gene regulation. The hnRNP L modulates 
the expression of the VEGFA transcript under hypoxic con-
ditions by competing with the binding of miRNAs in the 
VEGFA 3′-UTR (Jafarifar et al. 2011). Likewise, hnRNP I 
binds let-7 miRNA and human Argonaute2, therefore alter-
ing its association to human mRNAs (Engels et al. 2012).
The neuronal paralog of hnRNP I/PTB (nPTB) has 75 % 
homology with hnRNP I and has broadly the same effects 
on the regulation of RNA splicing. However, nPTB and 
PTB are mostly differentially expressed, leading to distinct 
outcomes for some neuronal-specific alternative splicing 
events (Sharma et al. 2005; Zhang et al. 2013a).
hnRNP K
Similar to hnRNP E1 and E2, hnRNP K has multiple 
nuclear and cytosolic functions, including the regulation of 
transcription (Stains et al. 2005), splicing (Cao et al. 2012), 
mRNA silencing (Fan et al. 2015), mRNA stability (Fukuda 
et al. 2009b) and translation (Habelhah et al. 2001). What 
makes hnRNP K different from the other hnRNPs is its 
functional versatility that is mediated by the capability to 
interact with multiple proteins through its K interactive 
region (Bomsztyk et al. 2004). In this way, hnRNP K can 
be placed at the center of a vast interaction network, ena-
bling it to play multiple roles in diverse cellular processes.
One of the processes in which hnRNP K was newly 
found to be involved in is the maintenance of ATP lev-
els upon cellular stress, by directly interacting with RNA 
binding motif protein 42 (RBM42) mRNA (Fukuda et al. 
2009b). The hnRNP K is also integrated in multiple signal 
transduction pathways by direct binding to the serotonin 
transporter (SERT) (Yoon et al. 2013). In addition, hnRNP 
K is found to interact with glycogen synthase-3β (GSK3β) 
mRNA, where it regulates various signaling pathways dur-
ing osteoclast differentiation (Fan et al. 2015).
There is strong evidence for hnRNP K to play an impor-
tant role in the post-transcriptional regulation of multiple 
genes involved in the cytoskeletal organization of axons, 
and hnRNP K is therefore found to be essential for axono-
genesis (Liu and Szaro 2011). This regulation is directed by 
the phosphorylation of hnRNP K by the c-Jun N-terminal 
kinase (JNK) (Hutchins and Szaro 2013). Corroborating 
this, the knockdown of hnRNP K results in the failure to 
create axons in developing Xenopus embryos (Liu et al. 
2008). In addition, a mouse model harboring an hnRNP K 
knockout allele results in reduced survival and increased 
tumor formation (Gallardo et al. 2015). The importance 
of hnRNP K during embryonal development was sup-
ported by the appreciation of high protein expression levels 
of hnRNP K in the central and peripheral nervous system 
(Blanchette et al. 2006).
hnRNP M/Q
The hnRNP M and Q are classified together, as these two 
RBPs have shared RNA-binding properties.
The hnRNP M is an abundant protein composed of three 
RRMs and is mostly present in the nucleus where it acts 
as a component of the spliceosome complex (Llères et al. 
2010). This association is further confirmed by the identi-
fication of hnRNP M in nuclear speckles that are enriched 
with splicing factors (Marko et al. 2010). Since the first 
report where hnRNP M was identified as a splicing regula-
tor for fibroblast growth factor receptor 2 (FGFR2) (Hov-
hannisyan and Carstens 2007), many reports followed and 
identified new targets: carcinoembryonic antigen-related 
cell adhesion molecule-1 (CEACAM1) (Dery et al. 2011), 
dopamine D2 receptor (D2M) (Park et al. 2011) and sur-
vival motor neuron 1 and 2 (SMN1 and SMN2) (Cho et al. 
2014).
The hnRNP Q (also known as SYNCRIP) has three iso-
forms called hnRNP Q1-Q3. They are all created by alter-
native splicing events. The N-terminus has three RRMs and 
an auxiliary domain composed of acidic residues. Although 
the exact molecular function of hnRNP Q is not yet fully 
understood, many steps of mRNA maturation have been 
found to be associated (Mourelatos et al. 2001). Recent 
studies in mice show a possible novel role for hnRNP Q2 
by binding to the poly(A)repeats of mRNAs and therefore 
competing with the poly(A)binding protein (PABP) (Svit-
kin et al. 2013). Interestingly, hnRNP Q contributes to the 
dendritic development and focal adhesion formation in 
neurons (Xing et al. 2012). Knockdown experiments in cor-
tical neurons of mice show an increased axonal and neurite 
length (Williams et al. 2015).
hnRNP P2 (FUS/TLS)
The hnRNP P2 is better known as the RNA binding protein 
fused in sarcoma/translated in liposarcoma (FUS/TLS), 
which is mutated in familial and sporadic ALS patients 
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(Vance et al. 2009). FUS/TLS contains one RRM and two 
glycine-rich domains, mediating its RNA-binding capaci-
ties. FUS/TLS contains an NLS and is predominantly 
located in the nucleus. The main part of the reported muta-
tions are located in the NLS of the C-terminus, resulting 
in an increased cytoplasmic retention (Waibel et al. 2010). 
The reported function of FUS/TLS will be further dis-
cussed in Box2—Role of hnRNPs in neurodegenerative 
diseases.
hnRNP R/U
The hnRNP R contains three RRMs and one RGG box, 
allowing specific interactions with its mRNA targets (Han 
et al. 2010). The hnRNP enhances c-fos transcription, by 
forming a complex with PC4 and Mediator (Fukuda et al. 
2009a). The presence of the above-mentioned RBDs sug-
gests additional post-transcriptional roles. More impor-
tantly, hnRNP R is also found in the cytosol where it regu-
lates cap-independent translation by binding to the IRES of 
target mRNAs (Lee et al. 2015).
The hnRNP U is the largest hnRNP family member and 
is mainly present in the nucleus where it is able to bind pre-
mRNA and ssDNA. It contains an N-terminus rich in acidic 
residues and a glycine-rich C-terminus, and within the mid-
dle of the protein a glutamine stretch together with an NLS 
sequence. It is believed that the RNA-binding capacities of 
hnRNP U are mediated by an RGG box in the glycine-rich 
C-terminus (Han et al. 2010). Because of its predominant 
nuclear localization, it is mainly involved in transcription 
(Bi et al. 2013) and alternative splicing (Vu et al. 2013). 
Interestingly, hnRNP U is needed for the accumulation of 
the lncRNA Xist on chromosome X, therefore epigeneti-
cally inactivating one of the two female X chromosomes to 
equalize gene expression with male mammals (Hasegawa 
et al. 2010).
Conclusions
The hnRNPs are RBPs responsible for packing and stabi-
lizing freshly transcribed pre-mRNAs. This early assembly 
step facilitates the removal of introns and alternative exons, 
leading to fully mature mRNAs ready to be exported out 
of the nucleus to translation-active sites in the cytoplasm. 
More recent studies have shown that hnRNPs have the 
potential to play diverse, but important roles in maintain-
ing mRNA homeostasis in the nucleus and cytoplasm. 
The functional versatility within the hnRNP family can 
arise from the ability of hnRNPs to form complexes with 
other hnRNP members and the potential to generate mul-
tiple alternatively spliced isoforms. Additional auxiliary 
domains, such as acid-, proline- and glycine-rich domains 
found in some hnRNPs to date, indicate that hnRNPs can 
be regulated in alternative ways. It is obvious that the 
insights into the functional regulation of hnRNPs is still 
limited and will definitely be explored in the following 
years. This additional knowledge will be beneficial for the 
development of new therapeutics as the number of hnRNPs 
involved in cancer and neurodegenerative disease is rapidly 
increasing.
To deeply investigate these shortcomings, it is of out-
most importance to have more structural information of 
the protein. The limited number of hnRNP structures cur-
rently available already points out the difficulties in study-
ing these proteins at a 3D level. Mainly, the highly variable 
loops/regions that reside in between the conserved RNA-
binding domains put extra challenges on these studies to 
succeed. Another question that needs to be answered is how 
the hnRNPs can specifically bind to their mRNA targets. 
To date, only a very small number of these protein–RNA 
complexes were resolved with high resolution using X-ray 
crystallography (Chaudhury et al. 2010a).
Besides the importance of flexible loops in the recogni-
tion of its targets, the secondary structure of RNA is of cru-
cial importance (Wu et al. 2004). To understand the com-
plexity of hnRNP binding to mRNA targets, there is a need 
for the determination of a 3D structure on the protein level, 
but preferentially also on the protein–RNA level. Bioin-
formatic tools will be useful to predict these protein–RNA 
interactions and to help resolve its 3D structure.
Of equal importance will be the identification of their 
mRNA targets. Already, efforts have been made for some 
hnRNPs, like for example hnRNP L, where cross-linked 
immunoprecipitation (CLIP) experiments shed light on 
the differential splicing regulation (Rossbach et al. 2014). 
As many hnRNPs have common RNA-binding properties, 
these generated data will contain additional information 
about the shared mRNA targets between hnRNPs. Addi-
tionally, the identification of various complexes formed 
between the hnRNP members will help us to better under-
stand their complementary functions.
It has become clear that hnRNPs are crucial players 
in the development of cancer and neurodegenerative dis-
ease. Looking at the important cellular functions of this 
group of RBPs, it would not be surprising to find them 
associated with other diseases in the near future. The rise 
in bio-informatics, improved biochemical approaches and 
in vivo models significantly increased our knowledge of 
RBPs in human diseases. However, the underlying patho-
mechanisms of many hnRNPs remain to be elucidated by 
studying their common and more specific functions related 
to disease. Nowadays, extensive research is performed on 
modulating the function of these RBPs to restore the dis-
ease phenotype. An example in cancer research is the 
recent unraveling of the epithelial–mesenchymal transition 
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pathway, which was shown to be regulated by hnRNP E1 
(Hussey et al. 2011). Looking at neurodegenerative dis-
eases, it was clearly shown that RNA-mediated toxic-
ity is a hallmark of many affected neurons. For example, 
the C9orf72 repeat expansion in ALS/FTLD patients are 
causative for RNA foci entrapping a huge collection of 
RBPs, which are, as a consequence, not functional (Mori 
et al. 2013). Future RNA-based therapies will focus on 
the attenuation of this RNA toxicity, achieved by antibod-
ies targeting the foci for degradation or by small molecules 
inhibiting repeat-associated non-ATG (RAN) translation. 
An alternative approach used in RNA-based therapy is to 
prevent the formation of toxic RNA foci. A critical step is 
to reduce the expression level of the disease-propagating 
protein, which can be done by protein translation arrest 
or mRNA degradation. Antisense oligonucleotide drugs 
(AODs) can directly bind to mRNA or interfere with the 
binding of miRNAs to their target. Promising research 
done on transgenic C9orf72 mice already showed that the 
level of mutant pathogenic mRNAs could be lowered by 
the administration of AODs, therefore reducing RNA tox-
icity and disease-associated symptoms (Lagier-Tourenne 
et al. 2013; Riboldi et al. 2014). This therapeutic strategy 
resulted in a first attempt to patent the use of AODs as a 
novel treatment for ALS/FTLD patients (Evers et al. 2015). 
Recent findings reporting a translational dysregulation in 
neurodegenerative diseases, caused by mutations in novel 
or known hnRNPs or by mutations in miRNAs, indicate the 
vulnerability of this regulation system in neurons. There-
fore, characterizing hnRNPs on a structural and functional 
level will be a crucial challenge.
BOX 1: role of hnRNPs in cancer
Many RBPs were identified to be involved in cancer and 
metastasis (Fig. 4). Because hnRNPs are important for 
gene expression regulation and show functional overlap; 
it is not surprising that many of the hnRNPs are keystones 
in tumor development. The hnRNP A1 is a major player 
and has been associated with different types of cancer and 
metastasis. Its expression is dramatically increased in lung 
cancer samples and is associated with tumor proliferation 
(Liu et al. 2015). In addition, the knockdown of hnRNP 
A2/B1 in MDA-MB-231 cells decreases cell invasion and 
thereby the proliferative effect of tumor cells (Loh et al. 
2015). Therefore, nanoparticle-aptamers were developed 
that recognize hnRNP A2/B1 in multiple tumor cells (Li 
et al. 2015). They consist of small oligomeric structures 
conjugated with nanoparticles, enabling them to easily 
reach cellular targets and to mediate a translational repres-
sion. Several oncogenes have been identified as being 
direct targets of hnRNP A1, such as Kirsten rat sarcoma 
viral oncogene homolog (KRAS), Harvey rat sarcoma 
viral oncogene homolog (HRAS) and a splice variant of 
Recepteur d’Origine Nantais (ΔRON), and can therefore 
control tumorigenesis and metastasis indirectly (Jean-
Philippe et al. 2013). Another oncogene named breast 
cancer (BRCA) was found to be regulated by hnRNP C. It 
was suggested that hnRNP C also acts as a key regulator 
controlling the metastatic potential of glioblastoma cells 
(Anantha et al. 2013).
Alternative splicing can increase the proteomic diver-
sity, which is necessary for the flexibility of the cell to 
respond to various conditions. It is therefore of outmost 
importance that the production of alternative transcripts is 
highly regulated. In case of dysregulation, splice variants 
can lead to aberrant protein isoforms having altered func-
tions. Recently, hnRNP H was identified as one of the first 
splicing factors leading to the production of HER2 splice 
variants, being important in the HER2 signaling pathway 
in cancer patients (Gautrey et al. 2015). Similarly, hnRNP 
M is involved in breast cancer where it activates the switch 
of alternative splicing, thereby precisely controlling CD44 
splice isoforms, leading to epithelial–mesenchymal transi-
tion (EMT) (Xu et al. 2014).
Probably, the best-studied hnRNP in cancer research is 
hnRNP E1. Its role in gene expression regulation, either 
on transcriptional or translational level, makes hnRNP 
E1 a key regulator of many cellular proteins, including 
proteins whose under- or overexpression can lead to dis-
ease. For example, the cyclin-dependent kinase inhibitor 
p21WAF is a key mediator of the p53-dependent cell cycle 
arrest, playing a role in tumor suppression (Oren and Rot-
ter 2010). The hnRNP E1 together with hnRNP E2 control 
the p21WAF mRNA half-life and therefore regulate the cell 
cycle via a p53-independent mechanism (Waggoner et al. 
2009). Additionally, hnRNP E1 increases the mRNA stabil-
ity of DNA polymerase η, which is a target of p53 tumor 
suppression (Ren et al. 2014). The p63, another transcrip-
tion factor and a p53 family protein, was also identified to 
be a target of hnRNP E1 mRNA stabilization (Cho et al. 
2013). Another example where hnRNP E1 translationally 
represses genes involved in tumorigenesis is its involve-
ment in EMT (Chaudhury et al. 2010b). Many hnRNP E1 
targets were identified to be associated with EMT, includ-
ing Dab2 and ILEI (Hussey et al. 2011). Supporting these 
findings, knockdown of hnRNP E1 results in the formation 
of tumors in mice after subcutaneous injection of NMuMG 
cells (Hussey et al. 2011).
BOX 2: role of hnRNPs in neurodegenerative diseases
Axons in the peripheral nervous system can be as long 
as 1 m and are therefore dependent on local translation. 
The regulation of translation at the presynaptic sites is of 
extreme importance as well as the transport of stabilized 
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mRNAs along the axonal cytoskeleton to these local trans-
lation hubs. Not surprisingly, hnRNPs, together with other 
RBPs, are crucial for the coordination of these processes. 
Perturbations in their functions and the control of target 
mRNAs can lead to multiple neurological diseases, such as 
ALS/FTLD, SMA and AD (Fig. 5) (Bekenstein and Soreq 
2013).
Mutations found in the prion-like domain located in 
hnRNP A1 and A2/B1 are causative for ALS/FTLD. In nor-
mal conditions, these hnRNPs have an intrinsic tendency to 
self-aggregate, because of their prion-like domains, but this 
tendency is abnormally increased by the disease-causing 
mutations (Kim et al. 2013). Although mutations in hnRNP 
A1 and A2/B1 further support the idea of an altered RNA 
metabolism as the underlying pathomechanism for ALS/
FTLD, it was found that these mutations are still a rare 
cause of the disease because of their low frequency (Le Ber 
et al. 2014). In addition, different genetic causes, like muta-
tions in the Tar DNA-binding protein 43 (TDP-43) and 
C9orf72 repeat expansions, were also found in ALS/FTLD 
patients. Motor neurons derived from induced pluripotent 
stem cells (iPSCs), originating from these ALS/FTLD 
patients, clearly showed the presence of hnRNP A1 and A2/
B1 in RNA foci, suggesting RNA toxicity via the sequestra-
tion of RBPs as a possible pathomechanism (Mohagheghi 
et al. 2015). More specifically, other hnRNPs can also be 
sequestered in these RNA foci as it was found for hnRNP 
A3, F, H and K in the spinal cord of ALS/FTLD patients 
(Cooper-Knock et al. 2015). Another hnRNP mutated in 
ALS patients is hnRNP P2, better known as FUS/TLS. 
The majority of the reported mutations are clustered in the 
C-terminal NLS leading to an increased cytoplasmic reten-
tion (Waibel et al. 2010).
Mutations in the survival motor neuron 1 (SMN1) gene 
encoding for an RNA-binding protein are causative for 
SMA. A paralog gene, SMN2, differs from SMN1 by a 
C/T transition in exon 7, which results in a lower expres-
sion of full-length SMN protein that cannot rescue the 
loss of SMN1 expression. A strategy used to treat SMA 
patients is to promote exon 7 retention in SMN2 (Porensky 
and Burghes 2013). Although a common pathomechanism 
between ALS/FTLD and SMA remains unclear, it was 
shown that TDP-43 and FUS/TLS co-localize in nuclear 
speckles together with SMN. The formation of such a com-
plex suggests that all three proteins function in spliceosome 
maintenance. Interestingly, the spliceosomal machinery is 
Fig. 4  The role of hnRNPs in cancer. Multiple hnRNPs are linked to 
cancer and metastasis. Many of them act on the level of alternative 
splicing leading to truncated proteins because of exon skipping. This 
modulation can be direct (e.g., hnRNP A1 and H) or indirect (e.g., 
hnRNP M) by competing with other RBPs like ESRP1. Additionally, 
hnRNP A1 and C are known transcriptional regulators acting on the 
promotor of KRAS, HRAS and BRCA, respectively. Specific cytosolic 
functions of hnRNP E1 are linked to the initiation and progression 
of cancers. More specifically, hnRNP E1 controls the mRNA stability 
and therefore mRNA half-life of specific genes (p21WAF, p63, DNA 
polymerase η) linked to cancer development. Recently, the discovery 
that hnRNP E1 is a key player in the TGF-β-mediated EMT resulted 
in deciphering RBP components involved in the translational control 
of known oncogenes like Dab-2 and ILEI
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Fig. 5  hnRNPs involved in SMA and ALS/FTLD. Due to extensive 
research in the last years, numerous hnRNPs are linked with SMA 
and ALS/FTLD. A single nucleotide substitution in the 5′-end of 
exon 7 in the SMN2 gene leads to exon skipping and consequently 
to a non-functional SMN protein. The hnRNP G can form a complex 
with the positive modifier, Tra2-β1, resulting in the retention of exon 
7. In addition, hnRNP Q can bind to the single nucleotide substitu-
tion, thereby avoiding exon 7 skipping. The hnRNP M targets a splic-
ing enhancer on exon 7 through the recruitment of U2AF65, leading 
to the production of a full-length transcript. In contrast, hnRNP A1 is 
found to be a negative regulator by binding to the splicing silencer, 
created by the single nucleotide substitution in SMN2. In addition, 
hnRNP A1 can bind to regions located in the introns of SMN1/2 (a). 
Besides being involved in alternative splicing, the hnRNP Q forms 
protein interactions with wild-type SMN, but is unable to bind to the 
truncated form. Similarly, the hnRNP R interacts with SMN in the 
cytosol of motor neurons; more specifically this interaction is present 
in the presynapses of neuromuscular junctions (b). C9orf72 repeat 
expansions causing ALS/FTLD leads to the formation of RNA foci 
containing hnRNP A1, A2/B1, A3, F, H and K suggesting RNA toxic-
ity via the sequestration of RBPs as a possible pathomechanism. Fur-
thermore, hnRNP A1 and A2/B1 are sequestered in cytosolic stress 
granules together with other RBPs causative for ALS/FTLD, such 
as FUS and TDP-43. Mutations found in the prion-like domain of 
hnRNP A1 and A2/B1 are causative for ALS/FTLD. In normal con-
ditions, these hnRNPs have an intrinsic tendency to self-aggregate, 
because of their prion-like domains, but this tendency is abnormally 
increased because of the disease-causing mutations (c)
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affected in both neurological diseases (Tsuiji et al. 2013). 
Currently, five hnRNPs (A1, G, M, Q and R) are linked to 
SMA (Kashima et al. 2007; Chen et al. 2008; Cho et al. 
2014; Dombert et al. 2014; Moursy et al. 2014) and are 
extensively discussed in Fig. 5.
The hnRNP C is linked to Alzheimer’s disease (AD) 
characterized by amyloid-b plaques formed by the amy-
loid-beta protein, which is a cleavage product of APP. The 
translational regulation of APP mRNA is therefore of cru-
cial importance and its sequence is a target of both fragile 
X mental retardation protein (FMRP) and hnRNP C. Both 
RBPs act competitively and influence APP translation in an 
opposing way (Borreca et al. 2015).
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